ZFIN ID: ZDB-FIG-180112-12
Facchinello et al., 2017 - nr3c1 null mutant zebrafish are viable and reveal DNA-binding-independent activities of the glucocorticoid receptor. Scientific Reports   7:4371 Full text @ Sci. Rep.
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Genes:
Fish:
Condition:
Anatomical Terms:
Stage: Day 5
PHENOTYPE:
Fish:
Condition:
Observed In:
Stage: Day 5

Fig. 3

gr s357/s357 and gr −/− 5-dpf zebrafish larvae in transgenic Tg(9xGCRE-HSV.Ul23:EGFP) background cannot respond to DEX treatment. (A) Fluorescence microscopy images of gr +/+, gr s357/s357 and gr −/− 5-dpf zebrafish larvae in transgenic Tg(9xGCRE-HSV.Ul23:EGFP)ia20 background. Treated larvae were subjected to 10 μM DEX treatment for 24 h (from 4 dpf to 5 dpf). (B) Integrated density analysis of fluorescence of 5-dpf zebrafish larvae of the three genotypes with or without DEX treatment. Homozygous zebrafish mutants deriving from heterozygous or homozygous parents were analysed separately. Values represent the mean ± SEM. Asterisks indicate that expression levels are significantly different from the control (two-way-ANOVA, *P < 0.05, ***P < 0.001). n = 15 larvae for each group. (C) qRT-PCR analysis of fkbp5, foxo3b and mmp-9 in gr +/+, gr s357/s357 and gr −/− 5-dpf zebrafish larvae deriving from homozygous parents with or without DEX treatment. Values represent the mean ± SEM. Different letters indicate statistically significant differences checked by two-way ANOVA followed by Tukey’s multiple-comparison test. fkbp5 (P < 0.01); foxo3b and mmp-9 (P < 0.001). Data were generated from four biological replicates.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
EGFP ia20Tg control Day 5 anatomical structure IFL
ia20Tg chemical treatment: dexamethasone Day 5 anatomical structure IFL
ia20Tg ; nr3c1ia30/ia30 control Day 5 anatomical structure IFL
ia20Tg ; nr3c1ia30/ia30 control Day 5 anatomical structure IFL
ia20Tg ; nr3c1ia30/ia30 chemical treatment: dexamethasone Day 5 anatomical structure IFL
ia20Tg ; nr3c1ia30/ia30 chemical treatment: dexamethasone Day 5 anatomical structure IFL
ia20Tg ; nr3c1s357/s357 control Day 5 anatomical structure IFL
ia20Tg ; nr3c1s357/s357 chemical treatment: dexamethasone Day 5 anatomical structure IFL
nr3c1s357/s357 ; ia20Tg control Day 5 anatomical structure IFL
nr3c1s357/s357 ; ia20Tg chemical treatment: dexamethasone Day 5 anatomical structure IFL
fkbp5 ia20Tg control Day 5 whole organism RTPCR
ia20Tg chemical treatment: dexamethasone Day 5 whole organism RTPCR
ia20Tg ; nr3c1ia30/ia30 control Day 5 whole organism RTPCR
ia20Tg ; nr3c1ia30/ia30 chemical treatment: dexamethasone Day 5 whole organism RTPCR
nr3c1s357/s357 ; ia20Tg control Day 5 whole organism RTPCR
nr3c1s357/s357 ; ia20Tg chemical treatment: dexamethasone Day 5 whole organism RTPCR
foxo3b ia20Tg control Day 5 whole organism RTPCR
ia20Tg chemical treatment: dexamethasone Day 5 whole organism RTPCR
ia20Tg ; nr3c1ia30/ia30 control Day 5 whole organism RTPCR
ia20Tg ; nr3c1ia30/ia30 chemical treatment: dexamethasone Day 5 whole organism RTPCR
nr3c1s357/s357 ; ia20Tg control Day 5 whole organism RTPCR
nr3c1s357/s357 ; ia20Tg chemical treatment: dexamethasone Day 5 whole organism RTPCR
mmp9 ia20Tg control Day 5 whole organism RTPCR
ia20Tg chemical treatment: dexamethasone Day 5 whole organism RTPCR
ia20Tg ; nr3c1ia30/ia30 control Day 5 whole organism RTPCR
ia20Tg ; nr3c1ia30/ia30 chemical treatment: dexamethasone Day 5 whole organism RTPCR
nr3c1s357/s357 ; ia20Tg control Day 5 whole organism RTPCR
nr3c1s357/s357 ; ia20Tg chemical treatment: dexamethasone Day 5 whole organism RTPCR
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
ia20Tg chemical treatment: dexamethasone Day 5 anatomical structure EGFP expression increased amount, abnormal
Day 5 whole organism mmp9 expression decreased amount, abnormal
Day 5 whole organism fkbp5 expression increased amount, abnormal
Day 5 whole organism foxo3b expression increased amount, abnormal
ia20Tg ; nr3c1ia30/ia30 control Day 5 anatomical structure EGFP expression decreased amount, abnormal
ia20Tg ; nr3c1ia30/ia30 control Day 5 anatomical structure EGFP expression decreased amount, abnormal
Day 5 whole organism fkbp5 expression decreased amount, abnormal
Day 5 whole organism foxo3b expression decreased amount, abnormal
ia20Tg ; nr3c1ia30/ia30 chemical treatment: dexamethasone Day 5 anatomical structure EGFP expression decreased amount, abnormal
ia20Tg ; nr3c1ia30/ia30 chemical treatment: dexamethasone Day 5 anatomical structure EGFP expression decreased amount, abnormal
ia20Tg ; nr3c1ia30/ia30 chemical treatment: dexamethasone Day 5 whole organism foxo3b expression decreased amount, abnormal
Day 5 whole organism fkbp5 expression decreased amount, abnormal
ia20Tg ; nr3c1s357/s357 control Day 5 anatomical structure EGFP expression decreased amount, abnormal
ia20Tg ; nr3c1s357/s357 chemical treatment: dexamethasone Day 5 anatomical structure EGFP expression decreased amount, abnormal
nr3c1s357/s357 ; ia20Tg control Day 5 anatomical structure EGFP expression decreased amount, abnormal
nr3c1s357/s357 ; ia20Tg control Day 5 whole organism foxo3b expression decreased amount, abnormal
nr3c1s357/s357 ; ia20Tg control Day 5 whole organism fkbp5 expression decreased amount, abnormal
nr3c1s357/s357 ; ia20Tg chemical treatment: dexamethasone Day 5 anatomical structure EGFP expression decreased amount, abnormal
Day 5 whole organism foxo3b expression decreased amount, abnormal
Day 5 whole organism mmp9 expression decreased amount, abnormal
Day 5 whole organism fkbp5 expression decreased amount, abnormal
Acknowledgments:
ZFIN wishes to thank the journal Scientific Reports for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ Sci. Rep.